SetPoint Medical Corp. is sharpening its focus on the rheumatoid arthritis therapy market, currently dominated by biopharmaceuticals, by channeling a good part of the $30m series D financing it recently raised into a multi-center Phase II clinical trial of its vagus nerve stimulation system.
The California company's technology is a rechargeable implant the size of a vitamin pill placed on the left side of the vagus nerve. It is programmed to stimulate specific fibers within the nerve, for a few minutes once a day, which then activates the body's natural inflammatory reflex